Paasa Logo
Cipher Pharmaceuticals Inc. logo
CPHTSXMarket closedOpens 9:30am ET

Cipher Pharmaceuticals Inc.

CA$13.89Last updated
-CA$0.17 (1.21%)Past day
Timezone

Cipher Pharmaceuticals Inc. (TSX: CPH) is trading at CA$13.89, about ₹945 at today's CAD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 1.21% today. Indian residents can buy Cipher Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:CA$13.95
Previous close:CA$14.06
Volume:24.00K

Today's low

CA$13.82

Today's high

CA$14.05

52 week low

CA$12.48

52 week high

CA$20.56

CPH opened at CA$13.95, closed previously at CA$14.06, and has traded between CA$12.48 and CA$20.56 over the past 52 weeks.

About

Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.

Country
CA
CEO
Craig J. Mull
Exchange listed on
TSX
Industry
Drug Manufacturers - Specialty & Generic
Base currency
CAD
Full Time Employees
5
Sector
Healthcare
IPO date
07/05/2004

Key statistics

Avg. volume

29.55K

Market cap

CA$352.69M

P/E Ratio

8.62

Price-to-sales ratio

5.06

Enterprise value

$240.69M

Free cash flow yield

10.80%

Debt-to-equity ratio

0.00

Return on equity

22.74%

ROIC

13.90%

Beta

0.46

Dividend yield

0.00%

Last dividend

CA$0.00

Financial overview

Revenue

$51.33M

Earnings per share

$1.09

Free cash flow

$30.22M

Net profit margin

58.81%

Gross margin

70.55%

EBITDA

$24.10M

Revenue growth

53.87%

Similar securities

This is not an investment recommendation

How to buy Cipher Pharmaceuticals from India

Indian residents can buy Cipher Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CAD.

  3. Search for Cipher Pharmaceuticals and place an order

    Find Cipher Pharmaceuticals by name or by its ticker, CPH, and choose an order type. Cipher Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Cipher Pharmaceuticals position in CAD and INR. Cipher Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Cipher Pharmaceuticals from India

Trading and taxes when buying Cipher Pharmaceuticals from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneCipher Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Cipher Pharmaceuticals stock?

Yes. Cipher Pharmaceuticals (CPH) has been listed on the Toronto Stock Exchange since 2004, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CAD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Cipher Pharmaceuticals share cost in rupees?

One Cipher Pharmaceuticals share is CA$13.89 — about ₹945 at a CAD/INR rate of 68.00 on 26 Sep 2026. Both the Cipher Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Cipher Pharmaceuticals from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

How are gains on Cipher Pharmaceuticals shares taxed in India?

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CAD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Cipher Pharmaceuticals price. Paasa issues a capital-gains statement for your return.

Does Cipher Pharmaceuticals pay a dividend?

No. Cipher Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Cipher Pharmaceuticals from India?

The Toronto Stock Exchange trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when Canada is on standard time. Orders can only execute during that window.

Do I have to declare Cipher Pharmaceuticals shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Cipher Pharmaceuticals holding, its cost and its closing value.

How do I sell Cipher Pharmaceuticals and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in CAD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.

Does the rupee rate affect what I make on Cipher Pharmaceuticals?

Yes. Cipher Pharmaceuticals is priced in CAD, so your rupee outcome combines the CAD move with the CAD/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.